| Rank | Ticker | Country | Price | Revenue | Analyst Rating | Analysts | IPO Year |
|---|---|---|---|---|---|---|---|
#1 | SKYT | United States | $27.36 | $442,139,000.00 | Buy | 5 | 2021 |
#2 | TGTX | United States | $26.92 | $2,785,000.00 | Strong Buy | 6 | 2008 |
#3 | ENR | United States | $16.48 | $2,952,700,000.00 | Buy | 7 | 2015 |
#4 | CDE | United States | $21.68 | $709,598,000.00 | Strong Buy | 5 | 1994 |
#5 | CSTM | France | $24.52 | $8,449,000,000.00 | Strong Buy | 4 | 2012 |
#6 | AMTB | United States | $20.91 | $0.00 | Buy | 4 | 2018 |
#7 | VRRM | United States | $15.16 | $132,969,000.00 | Buy | 5 | 2016 |
#8 | BWMN | United States | $28.24 | $490,017,000.00 | Strong Buy | 5 | 2021 |
#9 | XHR | United States | $14.37 | $1,078,500,000.00 | Buy | 6 | 2014 |
#10 | TRUP | United States | $24.80 | $1,439,305,000.00 | Buy | 4 | 2014 |
#11 | DAN | United States | $31.85 | $7,500,000,000.00 | Buy | 5 | 1998 |
#12 | PACS | United States | $33.76 | $5,288,932,000.00 | Strong Buy | 4 | 2024 |
#13 | ORN | United States | $10.51 | $852,260,000.00 | Strong Buy | 4 | 2007 |
#14 | BJRI | United States | $33.73 | $0.00 | Buy | 8 | 1996 |
#15 | EYE | United States | $25.94 | $1,987,488,000.00 | Strong Buy | 9 | 2017 |
#16 | ARI | United States | $10.34 | $271,589,000.00 | Buy | 4 | 2009 |
#17 | LEVI | United States | $18.09 | $6,282,000,000.00 | Strong Buy | 13 | 2019 |
#18 | AORT | United States | $36.18 | $298,836,000.00 | Strong Buy | 5 | 1996 |
#19 | VCYT | United States | $30.93 | $0.00 | Strong Buy | 8 | 2013 |
#20 | AMRX | United States | $12.12 | $0.00 | Strong Buy | 4 | 2018 |
#21 | CALX | United States | $49.75 | $510,367,000.00 | Strong Buy | 5 | 2009 |
#22 | LC | United States | $14.14 | $314,702,000.00 | Buy | 6 | 2008 |
#23 | BXMT | United States | $18.56 | $0.00 | Buy | 5 | 1998 |
#24 | KROS | United States | $10.99 | $243,864,000.00 | Buy | 8 | 2020 |
#25 | RUN | United States | $11.97 | $858,578,000.00 | Buy | 19 | 2015 |
#26 | APLS | United States | $18.39 | $1,003,782,000.00 | Buy | 20 | 2015 |
#27 | PFS | United States | $20.37 | $73,109,000.00 | Strong Buy | 4 | 2002 |
#28 | AFRM | United States | $46.30 | $3,224,412,000.00 | Buy | 29 | 2020 |
#29 | WGO | United States | $33.44 | $1,985,674,000.00 | Buy | 12 | 1994 |
#30 | WBD | United States | $27.42 | $0.00 | Buy | 20 | 2008 |
#31 | NVST | United States | $25.44 | $2,566,500,000.00 | Buy | 12 | 2019 |
#32 | ABM | United States | $38.67 | $8,745,900,000.00 | Buy | 5 | 1994 |
#33 | ALHC | United States | $17.11 | $3,948,719,000.00 | Buy | 10 | 2021 |
#34 | NMRK | United States | $13.86 | $3,294,024,000.00 | Buy | 6 | 2017 |
#35 | GTLB | United States | $22.83 | $759,249,000.00 | Buy | 28 | 2021 |
#36 | ARQT | United States | $22.87 | $376,072,000.00 | Strong Buy | 7 | 2020 |
#37 | BEAM | United States | $25.52 | $24,000.00 | Buy | 16 | 2019 |
#38 | ATRC | United States | $29.52 | $201,630,000.00 | Strong Buy | 7 | 2005 |
#39 | BILL | United States | $39.67 | $1,462,570,000.00 | Buy | 22 | 2019 |
#40 | ACAD | United States | $21.27 | $726,437,000.00 | Buy | 22 | 2000 |
#41 | SHC | United States | $13.31 | $1,163,617,000.00 | Buy | 7 | 2020 |
#42 | NRDS | United States | $10.37 | $836,600,000.00 | Buy | 6 | 2021 |
#43 | ADPT | United States | $12.44 | $276,976,000.00 | Strong Buy | 9 | 2019 |
#44 | IDYA | United States | $32.85 | $218,710,000.00 | Strong Buy | 16 | 2019 |
#45 | AZTA | United States | $21.38 | $593,821,000.00 | Strong Buy | 5 | 1996 |
#46 | VCEL | United States | $32.11 | $276,259,000.00 | Strong Buy | 5 | 1996 |
#47 | DRVN | United States | $10.53 | $2,339,588,000.00 | Buy | 8 | 2020 |
#48 | PHR | United States | $11.00 | $419,813,000.00 | Strong Buy | 17 | 2019 |
#49 | ARVN | United States | $12.48 | $262,600,000.00 | Buy | 21 | 2018 |
#50 | HFWA | United States | $25.09 | $0.00 | Buy | 4 | 1997 |
The FinQuota filters have identified what they believe to be the "Best Stocks Under $50 to Buy (March 12, 2026) | FinQuota" to buy now. However, please note that this information should not be considered as financial advice, as investing involves risks. We strongly recommend consulting with a qualified financial advisor before making any decisions regarding buying or selling stocks.